NDAORALCAPSULE
Approved
Jun 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
6/8 — Strong
JALYN (dutasteride and tamsulosin hydrochloride) by Viatris is 5-alpha reductase inhibitors [moa]. Approved for symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate, symptomatic bph in men with an enlarged prostate. First approved in 2010.
Drug data last refreshed 33m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JALYN is a fixed-dose combination of dutasteride (a 5-alpha reductase inhibitor) and tamsulosin (an alpha-blocker) delivered as an oral capsule. It treats symptomatic benign prostatic hyperplasia (BPH) by reducing prostate size and improving urinary symptoms through dual mechanism of action.
$0.001BPart D
LOE ApproachingDeclining
Product is in late-stage maturity with modest Part D spending; commercial teams are likely focused on defending market share against generics rather than expansion.
Mechanism of Action
5-alpha Reductase Inhibitors
Pharmacologic Class:
5-alpha Reductase Inhibitor
Worked on JALYN at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.